Detection of ROS1 Gene Rearrangement in Lung Adenocarcinoma: Comparison of IHC, FISH and Real-Time RT-PCR

@article{Shan2015DetectionOR,
  title={Detection of ROS1 Gene Rearrangement in Lung Adenocarcinoma: Comparison of IHC, FISH and Real-Time RT-PCR},
  author={Ling Shan and Fang Lian and Lei Guo and Tian Qiu and Yun Ling and Jianming Ying and Dongmei Lin},
  journal={PLoS ONE},
  year={2015},
  volume={10}
}
  • Ling Shan, Fang Lian, +4 authors Dongmei Lin
  • Published 2015
  • Medicine, Biology
  • PLoS ONE
  • AIMS To compare fluorescence in situ hybridization (FISH), immunohistochemistry (IHC) and quantitative real-time reverse transcription-PCR (qRT-PCR) assays for detection of ROS1 fusion in a large number of ROS1-positive lung adenocatcinoma (ADC) patients. METHODS Using IHC analysis, sixty lung ADCs including 16 cases with ROS1 protein expression and 44 cases without ROS1 expression were selected for this study. The ROS1 fusion status was examined by FISH and qRT-PCR assay. RESULTS Among 60… CONTINUE READING

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 54 CITATIONS, ESTIMATED 44% COVERAGE

    Immunohistochemical Detection of ROS1 Fusion

    VIEW 7 EXCERPTS
    HIGHLY INFLUENCED

    A Validation Study for the Use of ROS1 Immunohistochemical Staining in Screening for ROS1 Translocations in Lung Cancer

    VIEW 2 EXCERPTS
    HIGHLY INFLUENCED

    FILTER CITATIONS BY YEAR

    2015
    2020

    CITATION STATISTICS

    • 6 Highly Influenced Citations

    • Averaged 8 Citations per year from 2018 through 2020

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 21 REFERENCES

    ROS1 Immunohistochemistry for Detection of ROS1-Rearranged Lung Adenocarcinomas

    VIEW 1 EXCERPT

    Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma.

    VIEW 1 EXCERPT

    ROS1 fusions in Chinese patients with non-small-cell lung cancer.

    VIEW 2 EXCERPTS

    Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

    VIEW 8 EXCERPTS
    HIGHLY INFLUENTIAL